Key Highlights
- USD 12 million is the gross size of the registered direct offering announced on October 8, 2026 by China SXT Pharmaceuticals (NASDAQ:SXTC). It covered 8,000,000 Class A shares or pre-funded warrants at USD 1.50, with Univest Securities as sole placement agent, per the company release.
- USD 0.0787 is the latest published quote for China SXT Pharmaceuticals (NASDAQ:SXTC), up 14.39%. That is 94.8% below the USD 1.50 offering price (own arithmetic on two published numbers), a 19.1-fold gap within days that the filings reviewed do not explain.
- 204.47 million shares traded in the latest session, 3.54 times relative volume, or USD 16.1 million of turnover (own arithmetic). Published market capitalization of USD 0.70 to 0.82 million is 19.6 times smaller than that turnover, so it may exclude new issuance.
- 8,000,000 warrants went to the same investors, each exercisable at USD 2.75 for one share, or on a zero-cash basis for up to 9 shares, per the company release. That implies up to 72 million shares (own arithmetic), against 8,000,000 sold.
Price Action and Catalyst Review
China SXT Pharmaceuticals (NASDAQ:SXTC) announced the offering on October 8, 2026, with closing expected on October 9. Investors hold an option to buy up to another USD 12 million on the same terms during the 30 days after closing. The release does not state a use of proceeds. Implied average volume is 57.8 million shares (own arithmetic from the rounded relative volume). No company-specific catalyst was identified for the 14.39% rise in the filings and releases reviewed through October 16, 2026.
Capital Structure and Dilution
A zero-cash exercise converts a warrant into shares without paying the exercise price, with the count set by a formula, so new supply can exceed the shares sold. Prior financings were a USD 10 million registered direct offering on January 9, 2026 at USD 0.15 per share and a USD 9 million offering on July 23, 2026 at USD 2.00 per unit with warrants. Consolidations of 1-for-150 on February 3, 2026 and, as reported, 1-for-80 on August 10, 2026 compound to 12,000-to-1 (own arithmetic).
Listing Compliance and Risks
The quote is below the Nasdaq USD 1.00 minimum bid price. Nasdaq rules withhold a compliance period from companies whose reverse splits total 250-to-1 or more over two years, a threshold 12,000-to-1 exceeds, and a bid at or below USD 0.10 for ten consecutive trading days can trigger a delisting determination. A 2026 deficiency notice is not disclosed in the filings reviewed. Per-share EPS of negative 645.01 in published market data is a consolidation artefact, not independently confirmed. Monitor the 30-day option, Nasdaq letters, further consolidations and warrant exercises.
Where Things Stand
The stock is at USD 0.08 as dilution has outweighed a financing that was large relative to the company's size, though the 19.1-fold gap to the USD 1.50 offering price is unexplained in the filings reviewed; check it against exchange data. China SXT Pharmaceuticals (NASDAQ:SXTC) sold shares at USD 1.50, but zero-cash warrants, two consolidations this year and earlier offerings left supply above demand. The 14.39% rise on 204.47 million shares has no identified catalyst. Risks are further dilution, a Nasdaq delisting action and an unstated use of proceeds. The next catalysts are the 30-day investor option, any Nasdaq notice and the next financing filing.






Please wait processing your request...